GDNF Gene Therapy for Parkinson's Disease

Phase 1

Active, not recruiting

• Conditions: Parkinson's Disease
• Interventions: Biological: AAV2-GDNF

• Registration Number: NCT04167540
• Lead Sponsor: Brain Neurotherapy Bio, Inc.

Brief Summary

The objective of this Phase 1b investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a recent or a long-standing diagnosis of PD.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-11-07
• Study First Submitted QC: 2019-11-14
• Study First Posted: 2019-11-19
• Study Start: 2020-04-01
• Primary Completion: 2023-10-17
• Status Verified: 2024-08
• Last Update Submitted: 2024-08-12
• Last Update Posted: 2024-08-13
• Study Completion: 2027-06

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

• Male and female adults 35-75 years of age (inclusive)

• Diagnosed with Parkinson's disease

• Modified Hoehn and Yahr stage I-III OFF medication

• Time since receiving a clinical diagnosis of PD and disease severity consistent with one of the following:

  1. EITHER: Less than 5 years since clinical diagnosis of PD and mild to moderate UPDRS III OFF score
  2. OR: At least 4 years since clinical diagnosis of PD and moderate to severe UPDRS III OFF score

• Responsiveness to levodopa

Key

Read More

Exclusion Criteria

• Atypical parkinsonism
• Severe dyskinesia
• Presence of dementia, psychosis, substance abuse or qualify as "severe depression"
• Prior brain surgery (i.e. deep brain stimulator or DBS implantation) or other brain imaging abnormalities
• Receiving an investigational drug
• History of cancer or poorly controlled medical conditions that would increase surgical risk
• Inability to tolerate laying flat in an MRI or allergy to gadolinium

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Earlier stage PD	AAV2-GDNF	-
Later stage PD	AAV2-GDNF	-

Primary Outcome Measures

Name	Time	Method
The incidence of Treatment-Emergent Adverse Events (TEAE) assessed clinically by physical and neurological examinations	5 years	Evaluation of the safety and tolerability through the assessment of incidence of TEAE, identified by MedDRA preferred term and grouped by MedDRA System Organ Class, as well as clinically meaningful changes in clinical exams or laboratory assays.

Secondary Outcome Measures

Name	Time	Method
Motor symptoms as assessed by the Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS)	18 months	Change from baseline in the MDS-UPDRS. The MDS-UPDRS contains 4 subscales: Part I, non-motor aspects of experiences of daily living (13 items); Part II, motor aspects of experiences of daily living (13 items); Part III, motor examination (33 scores based on 18 items); Part IV, motor complications (6 items). The rating for each item, or sub-item, is from 0 (normal) to 4 (severe). The total score for each Part is obtained from the sum of the corresponding item scores.
Brain dopaminergic cell integrity as measured by DaTscan	18 months	Percentage and absolute changes in Ioflupane retention as a marker for dopamine transporter protein expressed by dopamine producing cells within the brain. Measured by quantitative analysis of DaTscan SPECT imaging.
Non-motor symptoms of Parkinson's disease as assessed by the Non-Motor Symptom Scale (NMSS)	18 months	Change from baseline in the NMSS. The NMSS evaluates 9 domains of non-motor of severity and frequency of PD symptoms associated with cardiovascular health, sleep and fatigue, mood and cognition, perceptual problems and hallucinations, attention and memory, gastrointestinal tract, urinary, sexual function, and a miscellaneous domain for other common non-motor conditions. Severity x frequency scores range 0-108, with 0 being less severe and less frequent.

Trial Locations

Locations (3)

University of California San Francisco; 🇺🇸 San Francisco, California, United States

University of California Irvine; 🇺🇸 Irvine, California, United States

The Ohio State University Medical Center; 🇺🇸 Columbus, Ohio, United States